Publication | Open Access

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial

Reflate Tb 2Pulmonary TuberculosisStandard Dose RaltegravirTreatment And PreventionTuberculosis PreventionAntiviral TherapyTuberculosisAnrs 12PharmacotherapyAntiviral DrugHivMedicine